TRIP13:A promising cancer immunotherapy target  

作　　者：Shengnan Jing Liya Zhao Liwen Zhao Yong‐Jing Gao Tianzhen He 

机构地区：[1]Institute of Pain Medicine and Special Environmental Medicine,Co‐innovation Center of Neuroregeneration,Nantong University,Nantong,Jiangsu,China

出　　处：《Cancer Innovation》2024年第6期1-10,共10页肿瘤学创新（英文）

基　　金：Large Instruments Open Foundation of Nantong University,Grant/Award Number:KFJN2375;National Natural Science Foundation of China,Grant/Award Number:82100557。

摘　　要：The tumor microenvironment(TME)facilitates tumor development through intricate intercellular signaling,thereby supporting tumor growth and suppressing the immune response.Thyroid hormone receptor interactor 13(TRIP13),an AAA+ATPase,modulates the conformation of client macromolecules,consequently influencing cellular signaling pathways.TRIP13 has been implicated in processes such as proliferation,invasion,migration,and metastasis during tumor progression.Recent studies have revealed that TRIP13 also plays a role in immune response suppression within the TME.Thus,inhibiting these functions of TRIP13 could potentially enhance immune responses and improve the efficacy of immune checkpoint inhibition.This review summarizes the recent research progress of TRIP13 and discusses the potential of targeting TRIP13 to improve immune‐based therapies for patients with cancer.

关 键 词：immune responses immune‐based therapies thyroid hormone receptor interactor 13 tumor microenvironment 

分 类 号：R730.51[医药卫生—肿瘤]